Rasmus Sørrig

CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1

Subodh Verma, Morten Bøttcher, Paul Brown, Dror Dicker et autres

BACKGROUND: Fixed-dose combination of semaglutide/cagrilintide (CagriSema 2.4 mg/2.4 mg) has demonstrated significant and clinically relevant body weight reductions in adults with overweight or obesity compared with placebo. METHODS: with ≥1 obesity-related complication, to once-weekly CagriSema 2.4 mg/2.4 mg, semaglutide 2.4 mg, cagrilintide …

ca, gb, dk, il, us, it (code pays fourni par la source)

ONCE-WEEKLY SUBCUTANEOUS SEMAGLUTIDE 2.4 MG IN ADOLESCENTS WITH OVERWEIGHT OR OBESITY

Ali Kabir, Daniel Weghuber, Timothy Barrett, Margarita Barrientos‐Pérez et autres

ONCE-WEEKLY SUBCUTANEOUS SEMAGLUTIDE 2.4 MG IN ADOLESCENTS WITH OVERWEIGHT OR OBESITY

Ali Kabir, Daniel Weghuber, Timothy Barrett, Margarita Barrientos‐Pérez et autres

Once-weekly semaglutide in adolescents with obesity

Daniel Weghuber, Timothy Barrett, Margarita Barrientos‐Pérez, Inge Gies et autres

Brief summary: This phase 3 double-blind, parallel-group, randomized, placebo-controlled trial over 68 weeks randomised (2:1) 201 adolescents with obesity to receive semaglutide 2.4 mg once weekly or placebo. Both groups also received lifestyle intervention. The primary endpoint was the percentage change in …

A model‐based approach to predict individual weight loss with semaglutide in people with overweight or obesity

Anders Strathe, Deborah B. Horn, Malte Selch Larsen, Domenica Rubino et autres

AIMS: To determine the relationship between exposure and weight-loss trajectories for the glucagon-like peptide-1 analogue semaglutide for weight management. MATERIALS AND METHODS: Data from one 52-week, phase 2, dose-ranging trial (once-daily subcutaneous semaglutide 0.05-0.4 mg) and two 68-week phase 3 trials (once-weekly …

dk, us, ca (code pays fourni par la source)

Author response for "A model‐based approach to predict individual weight loss with semaglutide in people with overweight or obesity"

Anders Bjerring Strathe, Deborah B. Horn, Malte Selch Larsen, Domenica Rubino et autres

Effect of semaglutide 2.4 mg on alanine aminotransferase in adolescents with obesity: a post-hoc analysis of the STEP TEENS trial

Daniel Weghuber, Inge Gies, Lise Lotte Gluud, Aske Thorn Iversen et autres

Reducing BMI below the obesity threshold in adolescents treated with once‐weekly subcutaneous semaglutide 2.4 mg

Aaron S. Kelly, Silva Arslanian, Dan Hesse, Aske Thorn Iversen et autres

OBJECTIVE: The aim of this study was to examine how improvement in BMI with the glucagon-like peptide-1 receptor agonist semaglutide translated to changes in BMI category in a post hoc analysis of the double-blind, phase 3a randomized controlled Semaglutide Treatment Effect in …

us, dk, de, at (code pays fourni par la source)

Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials

Hiddo J.L. Heerspink, Ellen M. Apperloo, Melanie J. Davies, Dror Dicker et autres

OBJECTIVE: These post hoc analyses of the Semaglutide Treatment Effect in People with obesity (STEP) 1-3 trials (NCT03548935, NCT03552757, and NCT03611582) explored the effects of semaglutide (up to 2.4 mg) on kidney function. RESEARCH DESIGN AND METHODS: STEP 1-3 included adults with …

nl, gb, il, dk, us, ca (code pays fourni par la source)

Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials

Hiddo J.L. Heerspink, Ellen M. Apperloo, Melanie J. Davies, Dror Dicker et autres

INTRODUCTION These post hoc analyses of the STEP 1–3 trials (NCT03548935, NCT03552757, NCT03611582) explored the effects of semaglutide (up to 2.4mg) on kidney function. RESEARCH DESIGN AND METHODS STEP 1–3 included adults with overweight/obesity; STEP 2 patients also had type 2 diabetes. …

Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials

Hiddo J.L. Heerspink, Ellen M. Apperloo, Melanie J. Davies, Dror Dicker et autres

INTRODUCTION These post hoc analyses of the STEP 1–3 trials (NCT03548935, NCT03552757, NCT03611582) explored the effects of semaglutide (up to 2.4mg) on kidney function. RESEARCH DESIGN AND METHODS STEP 1–3 included adults with overweight/obesity; STEP 2 patients also had type 2 diabetes. …

Semaglutide treatment for obesity in teenagers: a plain language summary of the STEP TEENS research study

Daniel Weghuber, Klaus Boberg, Dan Hesse, Ole Kleist Jeppesen et autres

What is this summary about? This is a plain language summary of the STEP TEENS research study, which was originally published in the New England Journal of Medicine . As more teenagers are living with obesity than ever before, researchers are searching …

at, dk, us (code pays fourni par la source)